Find the Perfect Plan for Your Investment Journey
C
Latest price
52 Week Range
A$228.61 - A$313.55
Next Earnings Date
Aug 19 2025 (Estimate)
Next Earnings Date
Aug 19 2025 (Est.)
Latest price
Market Cap | A$116.09B |
EV | A$136.18B |
Shares Outstanding | 484.21M |
Beta | 0.35 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | A$198.50 |
P/E 2025E | 23.48x |
P/Revenue 2025E | 4.72x |
Revenue | 12.80% |
EPS | 4.80% |
Operating Cash Flow | -8.60% |
Free Cash Flow | -7.60% |
Revenue | 6.50% |
EPS | 12.00% |
Operating Cash Flow | 19.30% |
Free Cash Flow | 25.90% |
Gross Margin 2025E | 54.20% |
Net Profit Margin 2025E | 19.02% |
ROE 2025E | 16.84% |
ROCE 2024 | 15.94% |
DPS 2025E | A$2.92 |
Payout Ratio 2025E | 44.79% |
Div. Yield 2025E | 1.21% |
DPS Last 3Y CAGR | 6.00% |
Price
%
1M
3M
6M
1Y
3Y
5Y
C
CSL Limited
CSL
Sector
Healthcare
Industry
Biotechnology
CEO
McKenzie, Paul
Employees
32,698
Website
www.csl.com.auIPO Date
1994-06-01
Headquarters
655 Elizabeth Street Melbourne, Victoria, 3000, Australia
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved